| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 3, 2005
Accepted on June 24, 2005
From the Department of Cardiovascular Medicine (H.S., A.T.) and the Kyushu University COE Program on Lifestyle-Related Diseases (H.S.), Kyushu University Graduate School of Medical Sciences, Fukuoka; and Japan Science and Technology Agency (H.S.), CREST, Tokyo, Japan.
Abstract--Rho-Kinase has been identified as one of the effectors of the small GTP-binding protein Rho. Accumulating evidence has demonstrated that Rho/Rho-kinase pathway plays an important role in various cellular functions, not only in vascular smooth muscle cell (VSMC) contraction but also in actin cytoskeleton organization, cell adhesion and motility, cytokinesis, and gene expressions, all of which may be involved in the pathogenesis of cardiovascular disease. At molecular level, Rho-kinase upregulates various molecules that accelerate inflammation/oxidative stress, thrombus formation, and fibrosis, whereas it downregulates endothelial nitric oxide synthase. The expression of Rho-kinase itself is mediated by protein kinase C/NF-
B pathway with an inhibitory and stimulatory modulation by estrogen and nicotine, respectively. At cellular level, Rho-kinase mediates VSMC hypercontraction, stimulates VSMC proliferation and migration, and enhances inflammatory cell motility. In animal studies, Rho-kinase has been shown to be substantially involved in the pathogenesis of vasospasm, arteriosclerosis, ischemia/reperfusion injury, hypertension, pulmonary hypertension, stroke and heart failure, and to enhance central sympathetic nerve activity. Finally, in clinical studies, fasudil, a Rho-kinase inhibitor, is effective for the treatment of a wide range of cardiovascular disease, including cerebral and coronary vasospasm, angina, hypertension, pulmonary hypertension, and heart failure, with a reasonable safety. Thus, Rho-kinase is an important therapeutic target in cardiovascular medicine.
This article has been cited by other articles:
![]() |
Q. Sun, P. Yue, Z. Ying, A. J. Cardounel, R. D. Brook, R. Devlin, J.-S. Hwang, J. L. Zweier, L. C. Chen, and S. Rajagopalan Air Pollution Exposure Potentiates Hypertension Through Reactive Oxygen Species-Mediated Activation of Rho/ROCK Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1760 - 1766. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-X. Qi, M.-J. Qu, D.-K. Long, B. Liu, Q.-P. Yao, S. Chien, and Z.-L. Jiang Rho-GDP dissociation inhibitor alpha downregulated by low shear stress promotes vascular smooth muscle cell migration and apoptosis: a proteomic analysis Cardiovasc Res, October 1, 2008; 80(1): 114 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yasue, Y. Mizuno, E. Harada, T. Itoh, H. Nakagawa, M. Nakayama, H. Ogawa, S. Tayama, T. Honda, S. Hokimoto, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1742 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Phrommintikul, L. Tran, A. Kompa, B. Wang, A. Adrahtas, D. Cantwell, D. J. Kelly, and H. Krum Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1804 - H1814. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I Converting Enzyme Levels Hypertension, October 1, 2007; 50(4): 792 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Nuno, V. P. Korovkina, S. K. England, and K. G. Lamping RhoA Activation Contributes to Sex Differences in Vascular Contractions Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1934 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Haydont, C Bourgier, and M-C Vozenin-Brotons Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity Br. J. Radiol., September 1, 2007; 80(Special_Issue_1): S32 - S40. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. van Nieuw Amerongen and V. W.M. van Hinsbergh Endogenous RhoA Inhibitor Protects Endothelial Barrier Circ. Res., July 6, 2007; 101(1): 7 - 9. [Full Text] [PDF] |
||||
![]() |
S. A. Hamid, H. S. Bower, and G. F. Baxter Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2598 - H2606. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. C. Manintveld, P. D. Verdouw, and D. J. Duncker The RISK of ROCK Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2563 - H2565. [Full Text] [PDF] |
||||
![]() |
M. Oka, N. Homma, L. Taraseviciene-Stewart, K. G. Morris, D. Kraskauskas, N. Burns, N. F. Voelkel, and I. F. McMurtry Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats Circ. Res., March 30, 2007; 100(6): 923 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gao, A. D. Portugal, S. Negash, W. Zhou, L. D. Longo, and J. Usha Raj Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L678 - L684. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nohria, M. E. Grunert, Y. Rikitake, K. Noma, A. Prsic, P. Ganz, J. K. Liao, and M. A. Creager Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease Circ. Res., December 8, 2006; 99(12): 1426 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Meyer-ter-Vehn, S. Sieprath, B. Katzenberger, S. Gebhardt, F. Grehn, and G. Schlunck Contractility as a Prerequisite for TGF-{beta}-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4895 - 4904. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hizume, K. Morikawa, A. Takaki, K. Abe, K. Sunagawa, M. Amano, K. Kaibuchi, C. Kubo, and H. Shimokawa Sustained Elevation of Serum Cortisol Level Causes Sensitization of Coronary Vasoconstricting Responses in Pigs In Vivo: A Possible Link Between Stress and Coronary Vasospasm Circ. Res., September 29, 2006; 99(7): 767 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. G. Versteilen, I. J. M. Korstjens, R. J. P. Musters, A. B. J. Groeneveld, and P. Sipkema Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney Am J Physiol Renal Physiol, September 1, 2006; 291(3): F606 - F611. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chrissobolis and C. G. Sobey Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease Stroke, August 1, 2006; 37(8): 2174 - 2180. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schubert Sphingosine-1-phosphate in the circulatory system: Cause and therapeutic target for vascular dysfunction? Cardiovasc Res, April 1, 2006; 70(1): 9 - 11. [Full Text] [PDF] |
||||
![]() |
L. H. Romer, K. G. Birukov, and J. G.N. Garcia Focal Adhesions: Paradigm for a Signaling Nexus Circ. Res., March 17, 2006; 98(5): 606 - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nagaoka, S. A. Gebb, V. Karoor, N. Homma, K. G. Morris, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat J Appl Physiol, March 1, 2006; 100(3): 996 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Noma, N. Oyama, and J. K. Liao Physiological role of ROCKs in the cardiovascular system Am J Physiol Cell Physiol, March 1, 2006; 290(3): C661 - C668. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |